Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial
Christopher L. Corless(Oregon Health & Science University), Ronald P. DeMatteo(University of Pennsylvania), Kouros Owzar(Duke University), Martin D. McCarter(University of Colorado Cancer Center), Charles D. Blanke(SWOG Cancer Research Network), George D. Demetri(Dana-Farber Cancer Institute), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Violetta Kolesnikova(Memorial Sloan Kettering Cancer Center), Karla V. Ballman(Mayo Clinic in Arizona), Margaret von Mehren(Temple University Health System), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Michael C. Heinrich(VA Portland Health Care System), Shreyaskumar Patel(The University of Texas MD Anderson Cancer Center), Peter W. T. Pisters(The University of Texas MD Anderson Cancer Center), Martin E. Blackstein(Mount Sinai Hospital)
Cited by 315
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k